Abstract: SA-PO186

Low Dose Aspirin Increases 15-Epi-Lipoxin A4 Levels in CKD Patients

Session Information

Category: Nutrition, Inflammation, and Metabolism

  • 1401 Nutrition, Inflammation, Metabolism


  • Goicoechea, Marian, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Verde, Eduardo, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  • Luno, Jose, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Sanchez-Nino, Maria Dolores, Fundacion Jimenez Diaz, Madrid, Spain
  • Ortiz, Alberto, Fundacion Jimenez Diaz, Madrid, Spain
  • Garcia de vinuesa, Maria soledad, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  • Quiroga, Borja, Hospital de La Princesa, Madrid, Spain
  • Morales, Enrique, HOSPITAL 12 DE OCTUBRE, MADRID, Spain
  • Fernandez Juarez, Gema, HOSPITAL DE ALCORCON, ALCORCON, Spain
  • De Sequera, Patricia, University Hospital Infanta Leonor, Madrid, MAD, Spain
  • Verdalles, Ursula, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Resolution of inflammation is regulated by endogenous lipid mediators, such as lipoxins and their epimers, including 15-epi-lipoxin A4 (15-epi-LXA4). However, there is no information on 15-epi-LXA4 and its in vivo regulation in chronic kidney disease (CKD) patients.


Study Design: Open label randomized clinical trial.
Setting & Participants: 50 participants with chronic kidney disease (CKD) stage 3 and 4 without prior cardiovascular disease (25 in the aspirin group and 25 in the standard group) followed for 46 months.
Intervention: Aspirin (100 mg/day) or standard treatment.
Aim: To analyze the effect of aspirin on plasma 15-epi-LXA4 levels and inflammatory markers in CKD patients.


Baseline plasma15-epi-LXA4 levels were lower in diabetic (1.22±0.99 ng/ml) than in non-diabetic CKD patients (2.05±1.06 ng/ml, p<0.001) and inversely correlated with glycosylated hemoglobin levels (r=-0.303, p=0.006). In multivariate analysis, diabetes was associated with lower 15-epi-LXA4 levels, adjusted for age, inflammatory markers and renal function (p=0.005). In the whole study population, 15-epi-LXA4 levels tended to increase after twelve months on aspirin (from mean±SD 1.84±1.06 to 2.04±0.75 ng/ml) and decreased in the standard care group (1.60±1.15 to 1.52±0.68 ng/ml, p=0.04). The aspirin effect on 15-epi-LXA4 levels was more striking in diabetic patients, increasing from 0.94±0.70 to 1.93±0.74 ng/ml, p=0.017.


Diabetic patients with CKD have lower circulating 15-epi-LXA4 levels than non-diabetic CKD patients. Low dose aspirin for 12 months increased 15-epi-LXA4 levels, especially in diabetic patients. Given its anti-inflammatory properties, this increase in 15-epi-LXA4 levels may contribute to the beneficial effects of low dose aspirin.


  • Other NIH Support